Solon Eiendom ASA (BIONOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Solon Eiendom ASA (BIONOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH127065D
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Solon Eiendom ASA (Solon Eiendom), formerly Bionor Pharma ASA, is a biopharmaceutical company focuses on development of proprietary therapeutic vaccine Vacc-4x. It develops vaccines for HIV and other deadly viruses. Solon Eiendom by utilizing its proprietary technology platform develops modified peptide based vaccines targeting rapidly mutating viruses. Its pipeline product portfolio includes four different vaccine candidates, namely, Vacc-4x, Vacc-C5, Vacc-HIV (combination of Vacc-4x and Vacc-C5) and Vacc-Flu. The company also manages a portfolio of nutritional and weight management supplements. It is formed as business combination between vaccine developer Bionor Immuno AS and the nutraceutical company Nutri Pharma ASA. Solon Eiendom is headquartered at Oslo, Norway.

Solon Eiendom ASA (BIONOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Solon Eiendom ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deal Details 10

Equity Offering 10

Bionor Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

Bionor Pharma Raises USD17 Million in Private Placement of Shares 10

Bionor Pharma to Raise USD11.6 Million in Rights Offering of Shares 12

Bionor Pharma Raises Additional USD6.38 Million in Rights Offering of Shares 13

Bionor Pharma to Raise USD6.38 Million in Private Placement of Shares 14

Bionor Pharma Raises USD5 Million in Private Placement of Shares 16

Bionor Pharma Raises USD9 Million in Private Placement of Shares 17

Bionor Pharma Completes Rights Offering Of Shares For US$3.4 Million 18

Bionor Pharma Completes Private Placement Of Shares For US$9.15 Million 19

Bionor Pharma Completes Private Placement Of Shares For US$9.6 Million 20

Asset Transactions 21

Axellus Completes Acquisition Of Nutrilett Trademarks From Bionor Pharma For US$18.3 Million 21

Solon Eiendom ASA-Key Competitors 22

Key Employees 23

Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Nov 16, 2016: Bionor Q3 2016 Interim Financial Report 25

Aug 23, 2016: Bionor Pharma: H1 2016 Interim Financial Report 26

May 11, 2016: Bionor: Q1 2016 Interim Financial Report 28

Feb 12, 2016: Bionor Q4 and Full Year 2015 Interim Financial Report 29

Corporate Communications 30

Dec 15, 2016: Solon Eiendom- Election of new Board of Directors and appointment of new CEO and CFO 30

Apr 26, 2016: Bionor Pharma: CEO leaves his position 31

Apr 26, 2016: Bionor pharma : CEO leaves his position 32

Other Significant Developments 33

Dec 19, 2016: Bionor Pharma-New name and new ticker from 19 December 2016 33

May 31, 2016: Update from the Board on clinical strategy and capital structure 34

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36

List of Figures

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Solon Eiendom ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Solon Eiendom ASA, Deals By Therapy Area, 2011 to YTD 2017 8

Solon Eiendom ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Bionor Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

Bionor Pharma Raises USD17 Million in Private Placement of Shares 10

Bionor Pharma to Raise USD11.6 Million in Rights Offering of Shares 12

Bionor Pharma Raises Additional USD6.38 Million in Rights Offering of Shares 13

Bionor Pharma to Raise USD6.38 Million in Private Placement of Shares 14

Bionor Pharma Raises USD5 Million in Private Placement of Shares 16

Bionor Pharma Raises USD9 Million in Private Placement of Shares 17

Bionor Pharma Completes Rights Offering Of Shares For US$3.4 Million 18

Bionor Pharma Completes Private Placement Of Shares For US$9.15 Million 19

Bionor Pharma Completes Private Placement Of Shares For US$9.6 Million 20

Axellus Completes Acquisition Of Nutrilett Trademarks From Bionor Pharma For US$18.3 Million 21

Solon Eiendom ASA, Key Competitors 22

Solon Eiendom ASA, Key Employees 23

Solon Eiendom ASA, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Solon Eiendom ASA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com